Clinical Trial Update: A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma [Phase 1]

View source ↗

Summary

This document describes a Phase 1 clinical trial evaluating LP-168 in participants with relapse or refractory B-cell lymphoma. The study is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• LP-168 (LP-168)

Snippet

Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. | Conditions: B-cell Lymphoma | Phase 1 | Status: RECRUITING